Skip survey header

2014 COG/ASPHO Joint Sponsorship: Cellular and Immunotherapy Approaches for Pediatric Leukemia and Lymphoma

Page One

This question requires a valid email address.
3. Objectives:
1. Discuss the mechanism of action of chimeric antigen receptor-modified T cells for childhood leukemia and potential for clinical benefit.
2. Discuss the potential side effects of therapy with chimeric antigen receptor-modified T cells for pediatric leukemia and understand the basis of potential management approaches.
3. Describe how chimeric antigen receptor-modified T cells may transform the treatment of children with relapsed or refractory ALL in years to come.
4. Recognize that common side effects of molecularly targeted agents differ from standard chemotherapy.
5. Develop an appreciation for carefully conducted trials to evaluate cancer therapies in children with short- and long-term side effects.
6. Describe some late effects of cancer treatment for children.
7. Recognize the differences in antigen specific T cells used clinically pre or post bone marrow transplant.
8. Describe the utility of donor-derived versus third-party T-cells.
9. Recognize Virus-specific T cells to extend beyond EBV without gene transfer.
*This question is required.Please rate your level of agreement with the following statement:
Presenters met stated learning objectives
4. Speaker Evaluation-Please rate your level of agreement for each speaker on the following: *This question is required.Presenter was effective
Space Cell 5-Agree Strongly4-Agree Moderately3-Neither Agree nor Disagree2-Disagree Moderately1-Disagree Strongly
Stephan A. Grupp, MD *This question is required
Lia Gore, MD *This question is required
Catherine Bollard, MD *This question is required
5. Demonstrated expertise in content area *This question is required.
Space Cell 5-Agree Strongly4-Agree Moderately3-Neither Agree nor Disagree2-Disagree Moderately1-Disagree Strongly
Stephan A. Grupp, MD *This question is required
Lia Gore, MD *This question is required
Catherine Bollard, MD *This question is required
6. Presentation was scientifically rigorous, balanced, and free of commercial bias *This question is required.
Space Cell 5-Agree Strongly4-Agree Moderately3-Neither Agree nor Disagree2-Disagree Moderately1-Disagree Strongly
Stephan A. Grupp, MD *This question is required
Lia Gore, MD *This question is required
Catherine Bollard, MD *This question is required
7. Please identify how you will change your practice as a result of attending this activity (select all that apply). *This question is required.
8. Please indicate any barriers you perceive in implementing these changes. *This question is required.
0%